Charles River Laboratories to acquire gene therapy CDMO Vigene Biosciences

Charles River Laboratories International has signed an all-cash deal worth $292.5 million to acquire Vigene Biosciences, a US-based gene therapy contract development and manufacturing organization ... Read More